AUTHORS
Jorge Arturo Hurtado Martinez, MD, MHSc, Martha Paola Anchondo Commesse, MD2, Edgar Ricardo Olivas Domínguez, MD3, Jael Antonio Liñán Esparza, MD4, Magaly Valeria Escobedo Cruz5, Diego Jose Fuentes Cañas, MD6, Jennifer M Ahlstrom, BA7, Samuel Bennion8, Jay R Hydren, PhD9
AFFILIATIONS
1 HealthTree Foundation, South Jordan, Utah, United States
2 HealthTree Foundation, South Jordan, Utah, United States
3 HealthTree Foundation, South Jordan, Utah, United States
4 HealthTree Foundation, South Jordan, Utah, United States
5 HealthTree Foundation, South Jordan, Utah, United States
6 HealthTree Foundation, South Jordan, Utah, United States
7 HealthTree Foundation, South Jordan, Utah, United States
8 HealthTree Foundation, South Jordan, Utah, United States
9 HealthTree Foundation, South Jordan, Utah, United States
ABSTRACT
Background
Potentially cured multiple myeloma (MM) patients have been observed in long-term transplant cohorts, showing possible survival plateaus. The 2026 IMS Myeloma Cure Summit discussed benchmarks for cure, such as response depth, sustained minimal residual disease (MRD) negativity, functional imaging, and time off therapy. However, there is no validated patient-level definition for cure. Registries from electronic health records (EHRs) vary in quality; and it's unclear if EHR data can effectively classify cure-associated factors. We assessed these components and examined if routine EHR data provides sufficient longitudinal evidence for classifying patients.
Methods
In this retrospective study we analyzed HealthTree registry participants with a documented diagnosis of MM and at least one evaluable line of therapy (LOT). Data was extracted on August 3, 2026. We assessed clinical and molecular features at the patient’s last follow-up. Focusing on treatment-free (TF) durations of ≥1y, absence of documented progression at the last LOT, availability of structured MRD results, documented complete response (CR) or better after the last LOT, and sustained MRD negativity at ≥1, 2, 3, 4, and 5y. TF required complete cessation of anti-MM therapy, with maintenance considered ongoing treatment. Sustained MRD negativity required no MRD-positive or documented progression result between the first and last negative test. To guard against infrequent testing, we required a minimum number of distinct negative test dates spread across each period: two tests for the ≥1–2y tiers, three for the ≥3–4y tiers, and four for the ≥5y tiers. Imaging-dependent classifications were deemed unevaluable due to lack of structured data . To meet strict TF-MRD criteria, patients required a TF duration of ≥5y while sustaining MRD negativity for ≥5y. Additionally, we defined a composite endpoint requiring a CR or better, a TF duration of ≥5y or current maintenance-only status, no documented progression, and no positive MRD result. Proportions were calculated using Wilson scoring for 95% confidence intervals.
Results
Among the 2,541 patients evaluated, 866 achieved a treatment outcome of CR or better. (34.1%, 95% CI 32.3–35.9%). Of these, 484 (55.9%, CI 52.6–59.2%) had no documented disease progression. 111 patients maintained treatment-free (TF) status for at least one year, (22.9%, CI 19.4–26.9%), 46 (9.5%, CI 7.2–12.4%) for ≥5y, 24 (5.0%, CI 3.4–7.3%) for ≥7y, and 12 (2.5%, CI 1.4–4.3%) for ≥10y. Furthermore, 57 of the 866 patients (6.6%, CI 5.1–8.4%) were on maintenance therapy alone during their last LOT, with 21 (36.8%, CI 25.5–49.8%) achieving ≥5y maintenance length. Among this group, 50 patients (87.7%, CI 76.8–93.9%) had no documented progression, and 19 (33.3%, CI 22.5–46.3%) met both criteria. MRD testing was documented for 268 patients (30.9%, CI 28.0–34.1%), with 78 (9.0%, CI 7.3–11.1%) undergoing sequencing-based testing. We found that 32 patients (11.9%, 95% CI 8.6–16.4%) maintained MRD negativity for ≥1y, dropping to 19 patients (7.1%, CI 4.6–10.8%) at ≥2y, 13 (4.9%, CI 2.9–8.1%) at ≥3y, 3 (1.1%, CI 0.4–3.2%) at ≥4y, and only 1 patient (0.4%, CI 0.1–2.1%) at ≥5y. The rates of sustained MRD negativity remained unchanged even after removing the required number of distinct test dates. This stability suggests that real-world (RW) clinical practice already aligns with our testing-frequency standards. No patients met the strict TF–MRD criteria (n=0). Nevertheless, 38 patients (1.5%, CI 1.1–2.0%) were identified within our composite endpoint; among them, 35 (92%) had never been MRD-tested, while only 3 had documented MRD-negative results.
Conclusion
Routine EHR data identified a clinically meaningful subgroup with deep responses and prolonged disease control, including treatment-free periods of up to 10 years and extended maintenance without documented progression. However, sustained MRD evidence was rare, and current imaging-dependent structured assessments were unevaluable, limiting the ability to confirm clinical and molecular features of cure. RW registries may therefore identify patients with cure-associated phenotypes more easily than confirming patient-level cure-associated factors. As new therapies emerge, RW data will be relevant for evaluating cure efficacy, however MRD testing frequency and imaging reports limit efforts to close this evidence gap and guide clinical practices towards cure-focused therapies.
DISCLOSURES
Jorge Arturo Hurtado Martinez, MD, MHSc: No relevant conflicts of interest to declare.